Biogen Idec

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

European Pharmaceutical Strategy; EU’s Intellectual Property framework; Orphan Medicinal Products Regulation; Industrial Strategy; Biosimilars & generics; EU Relative Efficacy Assessment and Health Technology Assessment; Digital framework and e-health topics; Patient access to innovation; Competition in the Pharmaceutical Sector; Non-Communicable Diseases; Rare Diseases; Demographic Change and healthy ageing, with a focus on Alzheimer’s disease; Mental and Brain Health.

https://www.biogen.com/

4

0.95

Please note that Biogen contributed to a number of EU consultations under its previous Registry number 966165310889-60:
List of contributions to public consultations:
• Revision of the EU general pharmaceuticals legislation Revision of the EU general pharmaceuticals legislation
• Revision of the EU legislation on medicines for children and rare diseases Medicines for children & rare diseases – updated rules
• Pharmaceutical Strategy - Timely patient access to affordable medicines Pharmaceuticals – safe and affordable medicines (new EU strategy)
• Digital health data and services – the European health data space

List of contributions to roadmaps:
• Pharmaceuticals – safe and affordable medicines (new EU strategy)
• Revision of the EU general pharmaceuticals legislation
• Digital health data and services – the European health data space

Data not provided by Register Secretariat due to GDPR

Data not provided by Register Secretariat due to GDPR

Companies & groups